2 Beaten-Down Stocks With Massive Upside Potential

The article highlights CRISPR Therapeutics (CRSP) and Viking Therapeutics (VKTX) as mid-cap biotech buy-the-dip candidates despite lagging over the past 12 months. For CRISPR, Casgevy remains largely non-material to results post-approval (late 2023) but has large upside potential (U.S. price ~$2.2M per treatment; ~60,000 target patients) and CRISPR reported $1.86B cash and equivalents as of Q1. For Viking, the market is excited by VK2735 phase 2 weight-management results and an oral Phase 2 formulation, alongside additional pipeline catalysts (VK2809 into Phase 3; VK0214 with FDA orphan designation), though the core risk is clinical setbacks that could pressure shares.

Analysis

This is less a fundamental inflection than a duration trade on binary biotech optionality. For CRSP, the market is still paying for a platform story while the near-term P&L remains hostage to adoption speed; that usually means the stock behaves like a long-dated call until a real revenue inflection appears. The hidden beneficiary is VRTX: it has the same Casgevy upside with far less balance-sheet risk and enough diversified earnings to absorb timing slippage, so incremental value creation is more likely to show up in VRTX than CRSP over the next 2-4 quarters.

VKTX is a different setup: the obesity market is crowded, so the key variable is not whether the category grows, but whether VKTX can prove differentiated tolerability and convenience versus entrenched GLP-1 leaders. The oral program matters more than the current injectable narrative because it is the only path to a broader commercial funnel; if that stumbles, the multiple can compress quickly even without a major safety issue. A further second-order risk is that improving competition from LLY/NVO can cap VKTX’s terminal share assumptions before phase 3 risk is even resolved.

Contrarian view: consensus is treating both names as “buy the dip” candidates, but the more likely near-term outcome is time decay, not immediate mean reversion. In the next 1-3 months, the stocks need catalysts to justify holding; otherwise the market will keep discounting dilution, trial timing, and commercial lag. The cleanest thesis is relative value, not outright beta.

Key Decisions for Investors

• Long VRTX / short CRSP as a 3-6 month relative-value pair; thesis is that VRTX monetizes Casgevy with lower execution risk while CRSP remains a catalyst-dependent balance-sheet story. Exit if CRSP shows a step-function in commercial uptake or VRTX updates imply slower partner economics than expected.
• Avoid chasing CRSP outright ahead of clinical readouts; only add on a post-catalyst drawdown if cash burn stays controlled and the next data set is clearly derisking. Falsifier: a second consecutive quarter of weak commercialization without offsetting pipeline progress.
• For VKTX, prefer a limited-risk call spread over stock if expressing upside into the next 6-12 months; the market is paying for obesity optionality, so defined-risk exposure is cleaner than paying full premium for a binary pipeline. Falsifier: oral VK2735 safety/tolerability or efficacy comes in below competitive thresholds.
• Use XBI only as a basket expression if the goal is biotech beta; single-name volatility in CRSP/VKTX is mostly event risk, not sector re-rating. This avoids being trapped in idiosyncratic downside if the market remains in a risk-off regime.
• Set a watch item on VRTX as the lower-risk way to own Casgevy upside; if partner economics start moving in the next 1-2 earnings cycles, VRTX should re-rate before CRSP does.